{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T08:39:03Z","timestamp":1776933543924,"version":"3.51.2"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ejmech.2020.113096","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T18:55:53Z","timestamp":1608144953000},"page":"113096","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Identification of N-phenyl-3-methoxy-4-pyridinones as orally bioavailable H3 receptor antagonists and \u03b2-amyloid aggregation inhibitors for the treatment of Alzheimer\u2019s disease"],"prefix":"10.1016","volume":"212","author":[{"given":"Minkui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongzhou","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5347-431X","authenticated-orcid":false,"given":"Rong","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2020.113096_bib1","series-title":"World Alzheimer Report 2018: the State of the Art of Dementia Research: New Frontiers","author":"Wortmann","year":"2018"},{"key":"10.1016\/j.ejmech.2020.113096_bib2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.neuropharm.2013.07.004","article-title":"Therapeutics of Alzheimer\u2019s disease: past, present and future","volume":"76","author":"Anand","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2020.113096_bib3","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S0140-6736(10)61349-9","article-title":"Alzheimer\u2019s disease","volume":"377","author":"Ballard","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2020.113096_bib4","doi-asserted-by":"crossref","first-page":"379","DOI":"10.7326\/0003-4819-148-5-200803040-00009","article-title":"Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline","volume":"148","author":"Raina","year":"2008","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejmech.2020.113096_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/gps.1402","article-title":"A\u00a0systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer\u2019s disease","volume":"21","author":"Takeda","year":"2006","journal-title":"Int. J. Geriatr. Psychiatr."},{"key":"10.1016\/j.ejmech.2020.113096_bib6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMra0909142","article-title":"Alzheimer\u2019s disease","volume":"362","author":"Querfurth","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2020.113096_bib7","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s00702-006-0578-3","article-title":"Alzheimer 100-highlights in the history of Alzheimer research","volume":"113","author":"Jellinger","year":"2006","journal-title":"J.\u00a0Neural. Transm."},{"key":"10.1016\/j.ejmech.2020.113096_bib8","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1126\/science.1132813","article-title":"100 years and counting: prospects for defeating Alzheimer\u2019s disease","volume":"314","author":"Roberson","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2020.113096_bib9","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrd2896","article-title":"Alzheimer\u2019s disease: strategies for disease modification","volume":"9","author":"Citron","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2020.113096_bib10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/med.20248","article-title":"Recent advances in the multitargetdirected ligands approach for the treatment of Alzheimer\u2019s disease","volume":"33","author":"Leon","year":"2013","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2020.113096_bib11","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.2174\/092986711797535245","article-title":"Multi-target-directed ligands in Alzheimer\u2019s disease treatment","volume":"18","author":"Bajda","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113096_bib12","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.2174\/1568026618666180112155424","article-title":"Multi-component reactions for multitargeted compounds for alzheimer\u2019s disease","volume":"17","author":"Ismaili","year":"2018","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113096_bib13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s40265-020-01268-1","article-title":"Sodium oligomannate: first approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2020.113096_bib14","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.2174\/1568026618666180116122921","article-title":"Multi-potent natural scaffolds targeting amyloid cascade: in search of alzheimer\u2019s disease therapeutics","volume":"17","author":"Chakraborty","year":"2018","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113096_bib15","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1755-5949.2010.00212.x","article-title":"Histamine pharmacology and new CNS drug targets","volume":"17","author":"Tiligada","year":"2011","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.ejmech.2020.113096_bib16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1021\/jm100064d","article-title":"Histamine H3 receptor as a drug discovery target","volume":"54","author":"Berlin","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113096_bib17","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/j.1476-5381.2012.02093.x","article-title":"Histamine H3 receptor antagonists in relation to epilepsy and neurodegeneration: a systemic consideration of recent progress and perspectives","volume":"167","author":"Bhowmik","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.113096_bib18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1517\/13543776.2014.848197","article-title":"New developments around histamine H3 receptor antagonists\/inverse agonists: a patent review (2010-present)","volume":"24","author":"\u0141azewska","year":"2014","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2020.113096_bib19","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s40265-016-0620-1","article-title":"Pitolisant: first global approval","volume":"76","author":"Syed","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2020.113096_bib20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40263-020-00703-x","article-title":"Pitolisant: a review in narcolepsy with or without cataplexy","volume":"34","author":"Lamb","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejmech.2020.113096_bib21","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of alzheimer\u2019s disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2020.113096_bib22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1021\/ml300058m","article-title":"The \u03b2-amyloid hypothesis in Alzheimer\u2019s disease: seeing is believing","volume":"3","author":"Kung","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2020.113096_bib23","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1039\/C1CS15112F","article-title":"Misfolded proteins in Alzheimer\u2019s disease and type II diabetes","volume":"41","author":"DeToma","year":"2012","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2020.113096_bib24","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1002\/anie.200802808","article-title":"Alzheimer\u2019s disease: from pathology to therapeutic approaches","volume":"48","author":"Jakob-Roetne","year":"2009","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2020.113096_bib25","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1021\/cr3000994","article-title":"The amyloid beta peptide: a chemist\u2019s perspective. Role in alzheimer\u2019s and fibrillization","volume":"112","author":"Hamley","year":"2012","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2020.113096_bib26","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1136\/postgradmedj-2013-201515rep","article-title":"The role of amyloid beta in the pathogenesis of Alzheimer\u2019s disease","volume":"90","author":"Gilbert","year":"2014","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.ejmech.2020.113096_bib27","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev.biochem.75.101304.123901","article-title":"Protein misfolding, functional amyloid, and human disease","volume":"75","author":"Chiti","year":"2006","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejmech.2020.113096_bib28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1021\/acschemneuro.5b00224","article-title":"Novel 1-Phenyl-3- hydroxy-4-pyridinone derivatives as multifunctional agents for the therapy of Alzheimer\u2019s Disease","volume":"7","author":"Sheng","year":"2016","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2020.113096_bib29","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1517\/17425255.2014.876006","article-title":"The role of drug metabolizing enzymes in clearance","volume":"10","author":"Di","year":"2014","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.ejmech.2020.113096_bib30","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1124\/dmd.108.023101","article-title":"Deferiprone glucuronidation by human tissues and recombinant UDP glucuronosyltransferase 1A6: an in\u00a0vitro investigation of genetic and splice variants","volume":"37","author":"Benoit-Biancamano","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2020.113096_bib31","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1152\/jn.1999.81.5.2164","article-title":"Enhancement of bistability in spinal motoneurons in\u00a0vivo by the noradrenergic alpha1 agonist methoxamine","volume":"81","author":"Lee","year":"1999","journal-title":"J.\u00a0Neurophysiol."},{"key":"10.1016\/j.ejmech.2020.113096_bib32","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nature10236","article-title":"Structure of the human histamine H1 receptor complex with doxepin","volume":"475","author":"Shimamura","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2020.113096_bib33","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1046\/j.1432-1033.2002.03271.x","article-title":"Solution structure of the Alzheimer amyloid beta-peptide (1\u221242) in an apolar microenviron-ment. Similarity with a virus fusion domain","volume":"269","author":"Crescenzi","year":"2002","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ejmech.2020.113096_bib34","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0091-3057(02)00745-1","article-title":"Differential in\u00a0vivo effects of H3 receptor ligands in a new mouse dipsogenia model","volume":"72","author":"Fox","year":"2002","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejmech.2020.113096_bib35","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbr.2004.11.008","article-title":"Effects of histamine H-3 receptor antagonists in two models of spatial learning","volume":"159","author":"Komater","year":"2005","journal-title":"Behav. Brain Res."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420310680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420310680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:19:18Z","timestamp":1759328358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523420310680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":35,"alternative-id":["S0223523420310680"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.113096","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of N-phenyl-3-methoxy-4-pyridinones as orally bioavailable H3 receptor antagonists and \u03b2-amyloid aggregation inhibitors for the treatment of Alzheimer\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.113096","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113096"}}